AGP Executive Report
Last update: 9 hours agoEye-Care Deal: Lupin’s VISUfarma has signed an exclusive €75m licensing partnership to commercialise YUVEZZI (carbachol + brimonidine) for presbyopia across the EU, UK, Switzerland, Norway and Iceland, with regulatory work and sales handled locally by VISUfarma. Public Safety Alert: A small glacial outburst flood is underway in Múlakvísl under Mýrdalsjökull, with elevated hydrogen sulphide near the source; people are warned not to linger by the river or glacier edge. Cancer Prevention Push: Iceland’s SPKC is urging parents to vaccinate children against HPV before routines get harder with the school year; uptake is still below the target group. Wound-Care Market Watch: Coloplast expects Kerecis wound-care growth to rebound from Jan 2027 after U.S. Medicare payment changes hit outpatient sales. Health & Travel Tips: Icelandair highlights how cabin dryness and pressure can worsen digestion and dehydration, recommending lighter, less salty meals for flights. Health Policy/Justice: Iceland renewed support to the ICC Trust Fund for Victims with a €10,000 contribution focused on victim needs.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration ]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/25163071-913113537-e8ba59374b15ad075fa57e2e962b9327ee5129aa-1280x720-100x56.png)
